Clomipramine, Urine
Clomipramine is a member of the class of drugs known as tricyclic antidepressants (TCAs). The use of TCAs first began in 1958 when imipramine use was shown to be particularly effective at treatment of melancholic depression. TCAs remained the first-line treatment for depression for approximately 30 years before the development of selective serotonin reuptake inhibitors (SSRIs); the use of antidepressants continues to be one of the primary ways to treat clinical depression. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorders, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease, or childhood enuresis.
In general, TCAs are lipophilic, have large volumes of distribution, are well absorbed, and reach peak serum concentrations within 2-12 hours. Most TCAs are metabolized by the cytochrome P450 system and many of the metabolites are biologically active. Clomipramine is metabolized to desmethylclomipramine, which is also biologically active. The half-lives of these particular drugs are quite variable. The half-life of clomipramine is between 19-37 hours (mean 32 hours). Many of the therapeutic ranges for these drugs have not been established or there is non-consensus.
The effects associated with clomipramine abuse include hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.
In conclusion, clomipramine and other TCAs are one of the most frequently encountered drugs of abuse due to the percentage of the population that is taking them, the frequency with which these drugs are prescribed, and their high potential for serious side effects.
- Therapeutic monitoring in blood
- Drug abuse evaluation
- Toxicity assessment
- Patient compliance
Urine
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 5 days
- Refrigeration: 7 days
- Frozen: 30 days
- Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
- Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):539-46. [PMID: 1183139]
- J Clin Psychiatry. 1983 May;44(5 Pt 2):27-34. [PMID: 6343361]
- J Iowa Med Soc. 1983 Aug;73(8):320-3. [PMID: 6355323]
- Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
- Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
- AACC Therapeutic Drug Monitoring and Toxicology 1989;11(4): 7-20.